Anaphylactoid reaction to pentastarch

Abstract

Purpose: To report a probable anaphylactoid reaction to pentastarch, a low molecular weight hydroxyethyl starch (HES) colloid solution. Clinical features: Following a dosed head injury, an 18-yr-old male was admitted to the Intensive Care Unit. Therapy was directed towards control of intracranial pressure (ICP) and maintenance of cerebral perfusion pressure (CPP). In the first 12 hr after admission, he had received 2500 ml polygeline (Haemaccel®, Hoechst Marion Roussel Ltd.) and a dopamine infusion (up to 10 μg·kg-1·min-1) titrated to achieve a mean arterial pressure (MAP) of ≤80 mmHg. Subsequent failure to achieve the target MAP resulted in commencement of a noradrenaline infusion (2.67 μg·min-1), and rapid administration of 500ml pentastarch (Pentaspan®, DuPont Pharmaceuticals). During the HES infusion, marked hypotension (MAP < 60 mmHg) developed associated with marked truncal urticaria. The hypotension was resistant to escalation of noradrenaline to 36 μg·min-1. Haemodynamic stability was rapidly restored and maintained with adrenaline boluses (total 450 μg) and infusion (1.67 μg·min-1). The remainder of the patient's ICU and hospital stay was unremarkable. A serum tryptase drawn in the first 40 min of the reaction was not elevated. Other biochemical markers were not assayed. Skin testing has not been carried out.